Publié le 20/02/2023
Patrick Jouandin, équipe Interactions métabolisme-épigénétique chez la Drosophile, jeune chef d’équipe ATIP-AVENIR
CDD 12 mois renouvelable
Publié le 20/02/23
Patrick Jouandin lab, young ATIP-AVENIR investigator, Montpellier Cancer Research Institute. Exciting projects,
state-of-the-art technologies, friendly and dynamic scientific environment, translational research. ATIP-AVENIR funded position, 12 months + 12 month.
Publié le 06/02/2023
Offer: The laboratory of Dr Nathalie Bonnefoy, Immunity and Cancer team, at the research cancer institute
of Montpellier (IRCM, INSERM U1194: https://www.ircm.fr) is looking for a full-time postdoctoral research
fellow to take on an exciting highly translational project to innovate in anti-cancer RAN based vaccine in the
context of a European consortium project.
The position is offered for 24 months with a possible reconduction for 1 year; selected candidate will work
under the supervision of Dr Julien Faget.
Keywords: Neutrophil, lung cancer, immunotherapy, single-cell multi-omics, epigenetics, image mass
cytometry, genetic engineered mouse models
Publié le 06/02/2023
Offer: The laboratory of Dr Nathalie Bonnefoy, Immunity and Cancer team, at the research cancer
institute of Montpellier (IRCM, INSERM U1194: https://www.ircm.fr) is looking for a full-time
postdoctoral research fellow to take on an exciting highly translational project to decipher tumor
promoting neutrophils biogenesis in non-small cell lung cancer patients and mouse models.
The position is offered for 24 months with a possible reconduction for 1 year; selected candidate will
work under the supervision of Dr Julien Faget.
Keywords: Neutrophil, lung cancer, immunotherapy, single-cell multi-omics, epigenetics, image mass
cytometry, genetic engineered mouse models
Situé dans le Parc Euromédecine, l'Institut de Recherche en Cancérologie de Montpellier (U1194) est localisé sur le Campus Val d'Aurelle (ICM, Institut régional du Cancer Montpellier / Val d'Aurelle).
Centre de Recherche U1194 soutenu par l'Inserm, l'Université de Montpellier et l'Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de
